{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:39:06Z","timestamp":1776818346855,"version":"3.51.2"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.brachy.2025.12.010","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T20:32:48Z","timestamp":1770323568000},"page":"509-514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dosimetric study of dose de-escalation using MRI-guidance for Pd-103 low-dose-rate brachytherapy in prostate cancer"],"prefix":"10.1016","volume":"25","author":[{"given":"Andrew","family":"Xue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7332-635X","authenticated-orcid":false,"given":"Meredith","family":"Akerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarush","family":"Gogineni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0017-8581","authenticated-orcid":false,"given":"Anthony","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Potters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1668-2611","authenticated-orcid":false,"given":"Bhupesh","family":"Parashar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2025.12.010_bib0001","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.brachy.2025.12.010_bib0002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2011.10827.x","article-title":"Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy","volume":"109","author":"Grimm","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2025.12.010_bib0003","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0360-3016(99)00499-X","article-title":"Palladium-103 brachytherapy for prostate cancer: analysis of the clinical efficacy and morbidity in 1450 patients","volume":"46","author":"Blasko","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.12.010_bib0004","first-page":"313","article-title":"American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy","volume":"18","author":"Yamada","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2025.12.010_bib0005","first-page":"41","article-title":"Single blind randomized phase II trial comparing hypofractionated and standard fractionated MRI-guided radiotherapy for localized prostate cancer (Hypo-FLAME trial)","volume":"164","author":"Lips","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2025.12.010_bib0006","first-page":"318","article-title":"MRI-guided adaptive radiotherapy for prostate cancer: the hypo-FLAME 2.0 study","volume":"115","author":"Kerkmeijer","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.12.010_bib0007","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boosting to the intraprostatic tumor in external beam radiotherapy for localized prostate cancer: results from the FLAME randomized phase 3 trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2025.12.010_bib0008","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.brachy.2023.09.001","article-title":"Viability of focal dose escalation to intraprostatic lesions using high-dose-rate brachytherapy","volume":"22","author":"Poder","year":"2023","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2025.12.010_bib0009","article-title":"MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer","volume":"12","author":"M\u00e9nard","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.brachy.2025.12.010_bib0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00345-023-04745-w","article-title":"Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review","volume":"42","author":"Dornisch","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.brachy.2025.12.010_bib0011","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.3390\/cancers15194888","article-title":"Focal boost in prostate cancer radiotherapy: a review of planning and clinical studies","volume":"15","author":"Zhao","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.brachy.2025.12.010_bib0012","doi-asserted-by":"crossref","first-page":"554","DOI":"10.5114\/jcb.2020.101688","article-title":"Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer","volume":"12","author":"Kunogi","year":"2020","journal-title":"J Contemp Brachyther"},{"key":"10.1016\/j.brachy.2025.12.010_bib0013","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.21037\/tau-21-508","article-title":"Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution","volume":"10","author":"Anderson","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.brachy.2025.12.010_bib0014","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.radonc.2016.09.014","article-title":"Hemi-gland focal low dose rate prostate brachytherapy: an analysis of dosimetric outcomes","volume":"121","author":"Laing","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2025.12.010_bib0015","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamaoncol.2020.7589","article-title":"Comparison of multiparametric magnetic resonance imaging-targeted biopsy with systematic transrectal ultrasonography biopsy for biopsy-naive men at risk for prostate cancer: a phase 3 randomized clinical trial","volume":"7","author":"Klotz","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.brachy.2025.12.010_bib0016","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00066-018-1364-5","article-title":"MRI-guided localization of the dominant intraprostatic lesion and dose analysis of volumetric modulated arc therapy planning for prostate cancer","volume":"195","author":"Tamihardja","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.brachy.2025.12.010_bib0017","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1118\/1.3246613","article-title":"AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: the 2009 update","volume":"36","author":"Nath","year":"2009","journal-title":"Med Phys"},{"key":"10.1016\/j.brachy.2025.12.010_bib0018","first-page":"522","article-title":"Dosimetric correlates of urethral toxicity after permanent seed prostate brachytherapy","volume":"13","author":"Hathout","year":"2014","journal-title":"Brachytherapy"},{"issue":"3 Suppl","key":"10.1016\/j.brachy.2025.12.010_bib0019","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.ijrobp.2009.03.078","article-title":"Radiation dose-volume effects in radiation-induced rectal injury","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.12.010_bib0020","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ijrobp.2007.11.066","article-title":"Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on outcomes","volume":"71","author":"Zelefsky","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.12.010_bib0021","first-page":"201","article-title":"Predictive factors for late urinary toxicity following low-dose-rate brachytherapy for prostate cancer","volume":"149","author":"Oike","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2025.12.010_bib0022","first-page":"118","article-title":"Magnetic resonance imaging-guided radiotherapy for prostate cancer: improved dosimetry and reduced toxicity","volume":"175","author":"Kishan","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2025.12.010_bib0023","article-title":"MRI-guided adaptive radiotherapy for prostate cancer: a systematic review","volume":"181","author":"Callaghan","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2025.12.010_bib0024","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/00000478-198812000-00001","article-title":"Zonal Distribution of Prostatic Adenocarcinoma: correlation with Histologic Pattern and Direction of Spread","volume":"12","author":"McNeal","year":"1988","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.brachy.2025.12.010_bib0025","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.radonc.2013.04.027","article-title":"Boosting imaging defined dominant prostatic tumors: a systematic review","volume":"107","author":"Bauman","year":"2013","journal-title":"Radiother Oncol"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472125003757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472125003757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:43:47Z","timestamp":1776815027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472125003757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1538472125003757"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2025.12.010","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosimetric study of dose de-escalation using MRI-guidance for Pd-103 low-dose-rate brachytherapy in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2025.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Brachytherapy Society.","name":"copyright","label":"Copyright"}]}}